This article is more than 5 years old. Information may no longer be current.
University appoints transplant director
Click Here to Manage Email Alerts
Warren Shlomchik, MD, has been named director of stem cell transplantation and cell therapies for the University of Pittsburgh’s division of hematology-oncology and the University of Pittsburgh Cancer Institute (UPCI).
He also will serve as UPCI’s scientific director of hematopoietic malignancies, as well as professor of medicine and immunology at the University of Pittsburgh School of Medicine.
Shlomchik previously served on the senior faculty at Yale Cancer Center at the Yale University School of Medicine. His appointment is effective March 1.
Warren Schlomchik
Shlomchik’s research has focused on the immunologic mechanisms underlying graft-versus-host disease (GVHD).
“Warren’s work has been invaluable in helping researchers understand more about the mechanisms of GVHD,” Edward Chu, MD, chief of the division of hematology/oncology and deputy director of UPCI, said in a press release. “His main priorities here in Pittsburgh will be to continue to conduct innovative, groundbreaking lab-based science, and to oversee the translation of that science into investigator-initiated clinical trials, which will be a huge advance for our transplant and hematopoietic malignancies clinical research program.”